Your browser doesn't support javascript.
loading
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis.
Bell, Christine; Anderson, James; Ganguly, Tanmoy; Prescott, James; Capila, Ishan; Lansing, Jonathan C; Sachleben, Richard; Iyer, Mani; Fier, Ian; Roach, James; Storey, Kristina; Miller, Paul; Hall, Steven; Kantor, Daniel; Greenberg, Benjamin M; Nair, Kavita; Glajch, Joseph.
Afiliación
  • Bell C; 1 Analytical Development, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Anderson J; 2 Pharmaceutical Sciences, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Ganguly T; 3 Research and Development, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Prescott J; 4 Analytical Chemistry, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Capila I; 5 Research, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Lansing JC; 5 Research, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Sachleben R; 6 Complex Generics Manufacturing, Technical Operations, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Iyer M; 7 Chemical Development and Manufacturing, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Fier I; 8 Program and Project Management, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Roach J; 9 Clinical Development and Regulatory Affairs, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Storey K; 10 Regulatory Affairs, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Miller P; 11 Medical Affairs and Communications, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
  • Hall S; 12 Medical Affairs, Sandoz, Inc, a Novartis Division, Princeton, NJ, USA.
  • Kantor D; 13 Division of Neurology, Florida Atlantic University, Boca Raton, FL, USA.
  • Greenberg BM; 14 Neurology and Neurotherapeutics, Pediatrics, UT Southwestern Medical Center, Dallas, TX, USA.
  • Nair K; 15 Department of Clinical Pharmacy, University of Colorado School of Pharmacy, Aurora, CO, USA.
  • Glajch J; 1 Analytical Development, Momenta Pharmaceuticals, Inc, Cambridge, MA, USA.
J Pharm Pract ; 31(5): 481-488, 2018 Oct.
Article en En | MEDLINE | ID: mdl-28847230
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Medicamentos Genéricos / Aprobación de Drogas / Esclerosis Múltiple Recurrente-Remitente / Acetato de Glatiramer / Desarrollo de Medicamentos Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Pharm Pract Asunto de la revista: FARMACIA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Adyuvantes Inmunológicos / Medicamentos Genéricos / Aprobación de Drogas / Esclerosis Múltiple Recurrente-Remitente / Acetato de Glatiramer / Desarrollo de Medicamentos Tipo de estudio: Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: J Pharm Pract Asunto de la revista: FARMACIA Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos